EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification of protein biomarkers for prediction of response to platinum‐based treatment regimens in patients with non‐small cell lung cancer

Franziska Böttger iD, Teodora Radonic, Idris Bahce, Kim Monkhorst, Sander R Piersma, Thang V Pham, Anne-Marie C Dingemans, Lisa M Hillen iD, Mariacarmela Santarpia, Elisa Giovannetti, Egbert F Smit, Sjaak A Burgers und 1 weitere

Molecular Oncology · 2024

DOI: 10.1002/1878-0261.13555 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2024. Verfasst von Franziska Böttger und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC - location VUmc, The Netherlands. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Associazione Italiana per la Ricerca sul Cancro (AIRC), KWF Kankerbestrijding, The Netherlands Organization for Scientific Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The majority of patients with resected stage II‐IIIA non‐small cell lung cancer (NSCLC) are treated with platinum‐based adjuvant chemotherapy (ACT) in a one‐size‐fits‐all approach. However, a significant number of patients do not derive clinical benefit, and no predictive patient selection biomarker is currently available. Using mass spectrometry‐based proteomics, we have profiled tumour resection material of 2 independent, multi‐centre cohorts of in total 67 patients with NSCLC who underwent ACT. Unsupervised cluster analysis of both cohorts revealed a poor response/survival sub‐cluster composed of ~ 25% of the patients, that displayed a strong epithelial‐mesenchymal transition signature and stromal phenotype. Beyond this stromal sub‐population, we identified and validated platinum response prediction biomarker candidates involved in pathways relevant to the mechanism of action of platinum drugs, such as DNA damage repair, as well as less anticipated processes such as those related to the regulation of actin cytoskeleton. Integration with pre‐clinical proteomics data supported a role for several of these candidate proteins in platinum response prediction. Validation of one of the candidates (HMGB1) in a third independent patient cohort using immunohistochemistry highlights the potential of translating these proteomics results to clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsBiomarkers, TumorHumansFemaleMaleAgedMiddle AgedProteomicsHMGB1 ProteinPlatinumCohort Studies

Stichwörter der Autor:innen

adjuvant chemotherapybiomarkerlung cancermass‐spectrometryplatinumproteomics

Substanzen

Biomarkers, TumorHMGB1 ProteinPlatinumHMGB1 protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC - location VUmc, The Netherlands.
  • OncoProteomics Laboratory, Cancer Center Amsterdam, Amsterdam UMC - location VUmc, The Netherlands.
  • Department of Pathology, Amsterdam UMC - location VUmc, The Netherlands.
  • Department of Pulmonary Diseases, Amsterdam UMC - location VUmc, The Netherlands.
  • Division of Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Department of Pulmonary Diseases, GROW School for Oncology & Developmental Biology, Maastricht University Medical Center, The Netherlands.

ORCID-Profile: Franziska Böttger, Lisa M Hillen, Connie R Jimenez

Förderung

  • Associazione Italiana per la Ricerca sul Cancro (AIRC)
  • KWF Kankerbestrijding
  • The Netherlands Organization for Scientific Research
  • VUmc-Cancer Center Amsterdam

Zitieren

APA

Böttger, F., Radonic, T., Bahce, I., Monkhorst, K., Piersma, S. R., Pham, T. V., Dingemans, A. C., Hillen, L. M., Santarpia, M., Giovannetti, E., Smit, E. F., Burgers, S. A., & Jimenez, C. R. (2024). Identification of protein biomarkers for prediction of response to platinum‐based treatment regimens in patients with non‐small cell lung cancer. Molecular Oncology. https://doi.org/10.1002/1878-0261.13555

Vancouver

Böttger F, Radonic T, Bahce I, Monkhorst K, Piersma SR, Pham TV, et al. Identification of protein biomarkers for prediction of response to platinum‐based treatment regimens in patients with non‐small cell lung cancer. Molecular Oncology. 2024. doi:10.1002/1878-0261.13555

BibTeX
@article{Bttger2024,
  author = {Böttger, Franziska and Radonic, Teodora and Bahce, Idris and Monkhorst, Kim and Piersma, Sander R and Pham, Thang V and Dingemans, Anne-Marie C and Hillen, Lisa M and Santarpia, Mariacarmela and Giovannetti, Elisa and Smit, Egbert F and Burgers, Sjaak A and Jimenez, Connie R},
  title = {Identification of protein biomarkers for prediction of response to platinum‐based treatment regimens in patients with non‐small cell lung cancer},
  journal = {Molecular Oncology},
  year = {2024},
  doi = {10.1002/1878-0261.13555}
}
Kostenlos starten →